Skip to main content

Advertisement

SpringerLink
Log in

The cost-effectiveness of risedronate in the treatment of osteoporosis: an international perspective

  • Original Article
  • Published:
Osteoporosis International Aims and scope Submit manuscript

Abstract

Introduction

Risedronate, a bisphosphonate for treatment and prevention of osteoporosis, has been shown in several clinical trials to reduce the risk of fractures in postmenopausal women with osteoporosis. The cost-effectiveness of risedronate treatment has previously been evaluated within different country settings using different model and analysis approaches. The objective of this study was to assess the cost-effectiveness of risedronate in postmenopausal women in four European countries—Sweden, Finland, Spain, and Belgium—by making use of the same modelling framework and analysis setup.

Methods

A previously developed Markov cohort model for the evaluation of osteoporosis treatments was used to estimate the cost-effectiveness of risedronate treatment. For each country, the model was populated with local mortality, fracture incidence, and cost data. Hip fractures, clinical vertebral fractures, and wrist fractures were included in the model.

Results

The incremental cost per quality-adjusted life years (QALY) gained from a 5-year intervention with risedronate compared to “no intervention” in 70-year-old women at the threshold of osteoporosis [T-score = −2.5 based on National Health and Nutrition Examination Survey (NHANES) III data] and previous vertebral fracture was estimated to be €860, €19,532, €11,782, and €32,515 in Sweden, Finland, Belgium, and Spain, respectively. Among 70-year-old women at the threshold of osteoporosis without previous fracture the estimated cost per QALY gained ranged from €21,148 (Sweden) to €80,100 (Spain). The differences in cost-effectiveness between countries are mainly explained by different costs (fracture and treatment costs), fracture risks, and discount rates. Based on cost per QALY gained threshold values found in the literature, the study results indicated risedronate to be cost effective in the treatment of elderly women with established osteoporosis in all the included countries.

Conclusions

At a hypothetical threshold value of €40,000 per QALY gained, the results in this study indicate that risedronate is a cost-effective treatment in elderly women at the threshold of osteoporosis (i.e., a T-score of −2.5) with prevalent vertebral fractures in Sweden, Finland, Belgium, and Spain.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6

Similar content being viewed by others

References

  1. Cummings SR, Melton, LJ (2002) Epidemiology and outcomes of osteoporotic fractures. Lancet 359:1761–1767

    Article  PubMed  Google Scholar 

  2. Report on Osteoporosis in the European Community - Action for Prevention (1998). European Commission – Employment & Social Affairs

  3. Kanis JA, Johnell O (2005) Requirements for DXA for the management of osteoporosis in Europe. Osteoporos Int 16:229–238

    Article  PubMed  CAS  Google Scholar 

  4. Delmas PD (2002) Treatment of postmenopausal osteoporosis. Lancet 359:2018–2026

    Article  PubMed  CAS  Google Scholar 

  5. Reginster J, Minne HW, Sorensen OH, Hooper M, Roux C, Brandi ML, Lund B, Ethgen D, Pack S, Roumagnac I, Eastell R (2000) Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Osteoporos Int 11:83–91

    Article  PubMed  CAS  Google Scholar 

  6. Harris ST, Watts NB, Genant HK, McKeever CD, Hangartner T, Keller M, Chesnut CH 3rd, Brown J, Eriksen EF, Hoseyni MS, Axelrod DW, Miller PD (1999) Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. JAMA 282:1344–1352

    Article  PubMed  CAS  Google Scholar 

  7. McClung MR, Geusens P, Miller PD, Zippel H, Bensen WG, Roux C, Adami S, Fogelman I, Diamond T, Eastell R, Meunier PJ, Reginster JY (2001) Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. N Engl J Med 344:333–340

    Article  PubMed  CAS  Google Scholar 

  8. Drummond M, O’Brien B, Stoddart G, Torrance G (1997) Methods for the economic evaluation of health care programmes. Oxford University Press, Oxford

    Google Scholar 

  9. Kanis JA, Borgstrom F, Johnell O, Jonsson B (2004) Cost-effectiveness of risedronate for the treatment of osteoporosis and prevention of fractures in postmenopausal women. Osteoporos Int 15:862–871

    Article  PubMed  CAS  Google Scholar 

  10. Borgstrom F, Zethraeus N (2003) Economic assessment based on a clinical study of risedronate. Fracture prevention in elderly women with osteoporosis is cost-effective. Lakartidningen 100:36–40

    PubMed  Google Scholar 

  11. Iglesias CP, Torgerson DJ, Bearne A, Bose U (2002) The cost utility of bisphosphonate treatment in established osteoporosis. Quart J Med 95:305–311

    CAS  Google Scholar 

  12. Hart WM, Rubio-Terres C, Burrell A, Aristegui I, Escobar-Jimenez Y (2002) Análisis farmacoeconómico del tratamiento de la osteoporosis postmenopáusica con risedronato o alendronato. REEMO 11:97–104

    Google Scholar 

  13. Brecht JG, Kruse HP, Felsenberg D, Mohrke W, Oestreich A, Huppertz E (2003) Pharmacoeconomic analysis of osteoporosis treatment with risedronate. Int J Clin Pharmacol Res 23:93–105

    PubMed  CAS  Google Scholar 

  14. Sonnenberg FA, Beck JR (1993) Markov models in medical decision making: a practical guide. Med Decis Making 13:322–338

    Article  PubMed  CAS  Google Scholar 

  15. Jonsson B, Christiansen C, Johnell O, Hedbrandt J, Karlsson G (1996) Cost-effectiveness of fracture prevention in established osteoporosis. Scand J Rheumatol Suppl 103:30–38

    PubMed  CAS  Google Scholar 

  16. Johnell O, Jonsson B, Jonsson L, Black D (2003) Cost effectiveness of alendronate (Fosamax) for the treatment of osteoporosis and prevention of fractures. Pharmacoeconomics 21:305–314

    Article  PubMed  Google Scholar 

  17. Jonsson L, Borgstrom F, Zethraeus N (2003) Cost-effectiveness of alendronate treatment of osteoporosis in Denmark. An economic evaluation based on the Fracture Intervention Trial. Ugeskr Laeger 165:4112–4116

    PubMed  Google Scholar 

  18. Zethraeus N, Johannesson M, Jonsson B (1999) A computer model to analyze the cost-effectiveness of hormone replacement therapy. Int J Technol Assess Health Care 15:352–365

    PubMed  CAS  Google Scholar 

  19. Kanis JA, Dawson A, Oden A, Johnell O, de Laet C, Jonsson B (2001) Cost-effectiveness of preventing hip fracture in the general female population. Osteoporos Int 12:356–361

    Article  PubMed  CAS  Google Scholar 

  20. Kanis JA, Johnell O, Oden A, De Laet C, Oglesby A, Jonsson B (2002) Intervention thresholds for osteoporosis. Bone 31:26–31

    Article  PubMed  CAS  Google Scholar 

  21. Kanis JA, Johnell O, Oden A, Jonsson B, Dawson A, Dere W (2000) Risk of hip fracture derived from relative risks: an analysis applied to the population of Sweden. Osteoporos Int 11:120–127

    Article  PubMed  CAS  Google Scholar 

  22. Tosteson AN, Jonsson B, Grima DT, O’Brien BJ, Black DM, Adachi JD (2001) Challenges for model-based economic evaluations of postmenopausal osteoporosis interventions. Osteoporos Int 12:849–857

    Article  PubMed  CAS  Google Scholar 

  23. Kanis JA, Johnell O, Oden A, Sembo I, Redlund-Johnell I, Dawson A, De Laet C, Jonsson B (2000) Long-term risk of osteoporotic fracture in Malmö. Osteoporos Int 11:669–674

    Article  PubMed  CAS  Google Scholar 

  24. Kannus P, Niemi S, Parkkari J, Palvanen M, Vuori I, Jarvinen M (1999) Hip fractures in Finland between 1970 and 1997 and predictions for the future. Lancet 353:802–805

    Article  PubMed  CAS  Google Scholar 

  25. Federaal Ministerie van Sociale Zaken, Volksgezondheid en Leefmilieu. Bestuur van de gezondheidszorgen. Commissie voor toezicht op en evaluatie van statistische gegevens die verband houden met de medische activiteiten in de ziekenhuizen. Rijksadministratif centrum. Brussel. Upon written request

  26. Statistiek NIvd. NIS-Dienst Verspreiding, Leuvenseweg 44, B-1000 Brussel. Upon written request

  27. Elffors I, Allander E, Kanis JA, Gullberg B, Johnell O, Dequeker J, Dilsen G, Gennari C, Lopes Vaz AA, Lyritis G et al. (1994) The variable incidence of hip fracture in southern Europe: the MEDOS Study. Osteoporos Int 4:253–263

    Article  PubMed  CAS  Google Scholar 

  28. Johnell O, Gullberg B, Kanis JA (1997) The hospital burden of vertebral fracture in Europe: a study of national register sources. Osteoporos Int 7:138–144

    Article  PubMed  CAS  Google Scholar 

  29. Marshall D, Johnell O, Wedel H (1996) Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. Br Med J 312:1254–1259

    CAS  Google Scholar 

  30. Looker AC, Wahner HW, Dunn WL, Calvo MS, Harris TB, Heyse SP, Johnston CC Jr, Lindsay R (1998) Updated data on proximal femur bone mineral levels of US adults. Osteoporos Int 8:468–489

    Article  PubMed  CAS  Google Scholar 

  31. Klotzbuecher CM, Ross PD, Landsman PB, Abbott TA 3rd, Berger M (2000) Patients with prior fractures have an increased risk of future fractures: a summary of the literature and statistical synthesis. J Bone Miner Res 15:721–739

    Article  PubMed  CAS  Google Scholar 

  32. Kanis JA, Johnell O, De Laet C, Johansson H, Oden A, Delmas P, Eisman J, Fujiwara S, Garnero P, Kroger H, McCloskey EV, Mellstrom D, Melton LJ, Pols H, Reeve J, Silman A, Tenenhouse A (2004) A meta-analysis of previous fracture and subsequent fracture risk. Bone 35:375–382

    Article  PubMed  CAS  Google Scholar 

  33. Cranney A, Tugwell P, Adachi J, Weaver B, Zytaruk N, Papaioannou A, Robinson V, Shea B, Wells G, Guyatt G (2002) Meta-analyses of therapies for postmenopausal osteoporosis. III. Meta-analysis of risedronate for the treatment of postmenopausal osteoporosis. Endocr Rev 23:517–523

    Article  PubMed  CAS  Google Scholar 

  34. Tonino RP, Meunier PJ, Emkey R, Rodriguez-Portales JA, Menkes CJ, Wasnich RD, Bone HG, Santora AC, Wu M, Desai R, Ross PD (2000) Skeletal benefits of alendronate: 7-year treatment of postmenopausal osteoporotic women. Phase III Osteoporosis Treatment Study Group. J Clin Endocrinol Metab 85:3109–3115

    Article  PubMed  CAS  Google Scholar 

  35. Stock JL, Bell NH, Chesnut CH 3rd, Ensrud KE, Genant HK, Harris ST, McClung MR, Singer FR, Yood RA, Pryor-Tillotson S, Wei L, Santora AC 2nd (1997) Increments in bone mineral density of the lumbar spine and hip and suppression of bone turnover are maintained after discontinuation of alendronate in postmenopausal women. Am J Med 103:291–297

    Article  PubMed  CAS  Google Scholar 

  36. Watts N, Barton I, Olszynski W, McKeever C, McClung M, Grauer A (2005) Sustained reduction of vertebral fracture risk in the year after discontinuation of risedronate treatment. Osteoporos Int 16:[Abstract s40]

  37. Statistical Yearbook of Sweden 2004

  38. Läkemedelsförmånsnämndens allmänna råd (2003). Stockholm

  39. Rovira J, Antonanzas F (1995) Economic analysis of health technologies and programmes. A Spanish proposal for methodological standardisation. Pharmacoeconomics 8:245–252

    Article  PubMed  CAS  Google Scholar 

  40. International Society for Pharmacoeconomics & Outcomes Research. Pharmacoeconomic Guidelines Around The World. http://www.ispor.org/PEguidelines/countrydet.asp?c=7&t=1. Access date: 2005-08-22

  41. A proposal for methodological guidelines for economic evaluation of pharmaceuticals (1995) Belgian Society for Pharmacoepidemiology, Brussels

  42. Kanis JA, Oden A, Johnell O, Jonsson B, de Laet C, Dawson A (2001) The burden of osteoporotic fractures: a method for setting intervention thresholds. Osteoporos Int 12:417–427

    Article  PubMed  CAS  Google Scholar 

  43. Instituto Nacional de Estadistica. Tablas de Mortalidad de la Población de España 1998–1999. http://www.ine.es/inebase/cgi/um?M=%2Ft20%2Fp319%2Fa1998%2F&O=pcaxis&N=&L=1. Access date: 2005-08-22

  44. Statistical Yearbook of Finland (2003). Statistics Finland, Helsinki

  45. Scientific Institute of Public Health, Unit of Epidemiology. Overall Mortality: Number of Deaths, Crude Rate (/100000): Belgium 1997: Females. http://www.iph.fgov.be/epidemio/spma. Access date: 2004-04-22

  46. Statistical Yearbook of Sweden (2004). Statistics Sweden, Stockholm

  47. Oden A, Dawson A, Dere W, Johnell O, Jonsson B, Kanis JA (1998) Lifetime risk of hip fractures is underestimated. Osteoporos Int 8:599–603

    Article  PubMed  CAS  Google Scholar 

  48. Johnell O, Kanis JA, Oden A, Sernbo I, Redlund-Johnell I, Petterson C, De Laet C, Jonsson B (2004) Mortality after osteoporotic fractures. Osteoporos Int 15:38–42

    Article  PubMed  CAS  Google Scholar 

  49. Kanis JA, Oden A, Johnell O, De Laet C, Jonsson B, Oglesby AK (2003) The components of excess mortality after hip fracture. Bone 32:468–473

    Article  PubMed  CAS  Google Scholar 

  50. Parker MJ, Anand JK (1991) What is the true mortality of hip fractures? Public Health 105:443–446

    Article  PubMed  CAS  Google Scholar 

  51. Cooper C, Atkinson EJ, Jacobsen SJ, O’Fallon WM, Melton LJ 3rd (1993) Population-based study of survival after osteoporotic fractures. Am J Epidemiol 137:1001–1005

    PubMed  CAS  Google Scholar 

  52. Cauley JA, Thompson DE, Ensrud KC, Scott JC, Black D (2000) Risk of mortality following clinical fractures. Osteoporos Int 11:556–561

    Article  PubMed  CAS  Google Scholar 

  53. Center JR, Nguyen TV, Schneider D, Sambrook PN, Eisman JA (1999) Mortality after all major types of osteoporotic fracture in men and women: an observational study. Lancet 353:878–882

    Article  PubMed  CAS  Google Scholar 

  54. Lundberg L, Johannesson M, Isacson D, Borgquist L (1999) Health state utilities in a general population in relation to age, gender and socioeconomic factors. Eur J Public Health 9:211–217

    Article  Google Scholar 

  55. Kind P, Hardman G, Macron S, UK Population Norms for EQ-5D (1999) Centre for Health Economics, University of York, York

    Google Scholar 

  56. Ohinmaa A, Sintonen H (1996) Quality of life of the Finnish population as measured by the EuroQol. Institut Universitari de Salut Publica de Catalunya, Barcelona

    Google Scholar 

  57. Dolan P (1997) Modeling valuations for EuroQol health states. Med Care 35:1095–1108

    Article  PubMed  CAS  Google Scholar 

  58. Zethraeus N, Borgström F, Johnell O, Kanis J, Jönsson B (2002) Costs and quality of life associated with osteoporosis related fractures - results from a Swedish survey. Working Paper Series in Economics and Finance, 512

  59. Kanis JA, Johnell O, Oden A, Borgstrom F, Zethraeus N, De Laet C, Jonsson B (2004) The risk and burden of vertebral fractures in Sweden. Osteoporos Int 15:20–26

    Article  PubMed  CAS  Google Scholar 

  60. Brazier JE, Green C, Kanis JA (2002) A systematic review of health state utility values for osteoporosis-related conditions. Osteoporos Int 13:768–776

    Article  PubMed  CAS  Google Scholar 

  61. National Osteoporosis Foundation (1998) Osteoporosis: review of the evidence for prevention, diagnosis and treatment and cost-effective analysis. Osteoporos Int 8(Suppl 4):1–88

    Google Scholar 

  62. Gabriel SE, Kneeland TS, Melton LJ 3rd, Moncur MM, Ettinger B, Tosteson AN (1999) Health-related quality of life in economic evaluations for osteoporosis: whose values should we use? Med Decis Making 19:141–148

    Article  PubMed  CAS  Google Scholar 

  63. Cranny A, Coyle D, Wells G, Jolly E, Tugwell P (2001) The psychometric properties of patient preferences in osteoporosis. J Rheumatology 28:132–137

    Google Scholar 

  64. Merlino LA, Bagchi I, Taylor TN, Utrie P, Chrischilles E, Sumner DR, Mudano A, Saag KG (2001) Preferences for fractures and other glucocorticoid-associated adverse events among rheumatoid arthritis patients. Med Decis Making 21:122–132

    Article  PubMed  CAS  Google Scholar 

  65. Hallberg I, Rosenqvist AM, Kartous L, Lofman O, Wahlstrom O, Toss G (2004) Health-related quality of life after osteoporotic fractures. Osteoporos Int 15:834–841

    Article  PubMed  CAS  Google Scholar 

  66. Oleksik A, Lips P, Dawson A, Minshall ME, Shen W, Cooper C, Kanis J (2000) Health-related quality of life in postmenopausal women with low BMD with or without prevalent vertebral fractures. J Bone Miner Res 15:1384–1392

    Article  PubMed  CAS  Google Scholar 

  67. Tosteson AN, Gabriel SE, Grove MR, Moncur MM, Kneeland TS, Melton LJ 3rd (2001) Impact of hip and vertebral fractures on quality-adjusted life years. Osteoporos Int 12:1042–1049

    Article  PubMed  CAS  Google Scholar 

  68. Hall SE, Criddle RA, Comito TL, Prince RL (1999) A case-control study of quality of life and functional impairment in women with long-standing vertebral osteoporotic fracture. Osteoporos Int 9:508–515

    Article  PubMed  CAS  Google Scholar 

  69. Jonsson B, Christiansen C, Johnell O, Hedbrandt J, Karlsson G (1996) Cost-effectiveness of fracture prevention in established osteoporosis. Scand J Rheumatol 103(Suppl):30–38; discussion 39–40

    PubMed  CAS  Google Scholar 

  70. Ekman M, Zethraeus N, Dahlstrom U, Hoglund C (2002) Cost-effectiveness of bisoprolol in chronic heart failure. Lakartidningen 99:646–650

    PubMed  Google Scholar 

  71. Sacristan JA, Oliva J, Del Llano J, Prieto L, Pinto JL (2002) What is an efficient health technology in Spain? Gac Sanit 16:334–343

    PubMed  CAS  Google Scholar 

  72. Raftery J (2001) NICE: faster access to modern treatments? Analysis of guidance on health technologies. Br Med J 323:1300–1303

    Article  CAS  Google Scholar 

  73. Kanis JA, Jonsson B (2002) Economic evaluation of interventions for osteoporosis. Osteoporos Int 13:765–767

    Article  PubMed  CAS  Google Scholar 

  74. Macroeconomics and Health: investing in health for economic development. Report of the Commission on Macroeconomics and Health (2001) Geneva

  75. Hart W, Rubio-Terres C, Burrell A, Aristegui I, Escobar-Jimenez Y (2002) Análisis farmacoeconómico del tratamiento de la osteoporosis postmenopáusica con risedronato o alendronato. REEMO 11

  76. Kanis JA, Johnell O, Oden A, Sembo I, Redlund-Johnell I, Dawson A, De Laet C, Jonsson B (2000) Long-term risk of osteoporotic fracture in Malmo. Osteoporos Int 11:669–674

    Article  PubMed  CAS  Google Scholar 

  77. Zethraeus N, Stromberg L, Jonsson B, Svensson O, Ohlen G (1997) The cost of a hip fracture. Estimates for 1,709 patients in Sweden. Acta Orthop Scand 68:13–17

    Article  PubMed  CAS  Google Scholar 

  78. Sintonen H, Vokkolainen A, Alhava E (2002) Osteoporoottisten lonkkamurtumien taloudelliset ja elämänlaadulliset seuraukset. Stakes Aiheita 34–35

  79. Autier P, Haentjens P, Bentin J, Baillon JM, Grivegnee AR, Closon MC, Boonen S (2000) Costs induced by hip fractures: a prospective controlled study in Belgium. Belgian Hip Fracture Study Group. Osteoporos Int 11:373–380

    Article  PubMed  CAS  Google Scholar 

  80. StadsledningskontoretsRedovisningsstab (2003) Stockholms stads budgetavräkning 2002. Stadsledningskontorets Redovisningsstab, Stockholm

  81. Hujanen T (2003) Terveydenhuollon yksikkökustannukset Suomessa vuonna 2001 Stakes Aiheita 1/2003, Helsinki

  82. Belgian Social Security System. http://www.riziv.be/insurer/fr/rate/pdf/2004/doctors/raad-20041001-fr.pdf. Access date: 2005-07-02

  83. Honorato J, Gomez-Outes A, Navarro-Quilis A, Martinez-Gonzalez J, Rocha E, Planes A (2004) Pharmacoeconomic analysis of bemiparin and enoxaparin as prophylaxis for venous thromboembolism in total knee replacement surgery. Pharmacoeconomics 22:885–894

    Article  PubMed  CAS  Google Scholar 

  84. The Swedish Association of the Pharmaceutical Industry. http://www.fass.se/LIF/produktfakta/artikel_produkt.jsp?NplID=19991007000217&DocTypeID=7&UserTypeID=2. Access date: 2005-05-06

  85. Yliopiston Apteekki. http://www.yliopistonapteekki.fi/searchProductInfo.do?searchResultByProductName=OPTINATE+TABLETTI+5MG&manufacturer=AVENTI. Access date: 2005-05-03

  86. Centre Belge d´Information Pharmacothérapeutique. http://www.cbip.be/ggr/index.cfm?ggrWelk=/nindex/ggr/stof/IN_R.cfm. Access date: 2005-07-25

  87. Base de datos medicamentos. http://pfarmals.portalfarma.com/default.asp. Access date: 2005-07-26

  88. Priser för södra sjukvårdsregionen - Vårdtjänster per klinik (2003) Universitetssjukhuset i Lund

  89. Osteoporosis in the European Community: A Call to Action: An audit of policy developments since 1998 (2001) International Osteoporosis Foundation

Download references

Author information

Authors and Affiliations

  1. Stockholm Health Economics, Klarabergsgatan 33 3tr, SE-111 21, Stockholm, Sweden

    F. Borgström & Å. Carlsson

  2. Medical Management Centre, Karolinska Institutet, Stockholm, Sweden

    F. Borgström

  3. Department of Public Health, University of Helsinki, Helsinki, Finland

    H. Sintonen

  4. Leuven University Center for Metabolic Bone Diseases and Division of Geriatric Medicine, Katholieke Universiteit Leuven, Leuven, Belgium

    S. Boonen

  5. Department of Orthopaedics and Traumatology, Academisch Ziekenhuis van de Vrije Universiteit Brussel, Brussels, Belgium

    P. Haentjens

  6. Procter & Gamble Pharmaceuticals, Mason, OH, USA

    R. Burge

  7. Division of Pharmaceutical Sciences, College of Pharmacy, University of Cincinnati, Cincinnati, OH, USA

    R. Burge

  8. Department of Orthopaedics, Malmö General Hospital, Stockholm, Sweden

    O. Johnell

  9. Department of Economics, Stockholm School of Economics, Stockholm, Sweden

    B. Jönsson

  10. Centre for Metabolic Bone Diseases (WHO Collaborating Centre), University of Sheffield Medical School, Sheffield, UK

    J. A. Kanis

Authors
  1. F. Borgström
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Å. Carlsson
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. H. Sintonen
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. S. Boonen
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. P. Haentjens
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. R. Burge
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. O. Johnell
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. B. Jönsson
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. J. A. Kanis
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to F. Borgström.

Additional information

Financial support was obtained via an unrestricted grant from The Alliance for Better Bone Health.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Borgström, F., Carlsson, Å., Sintonen, H. et al. The cost-effectiveness of risedronate in the treatment of osteoporosis: an international perspective. Osteoporos Int 17, 996–1007 (2006). https://doi.org/10.1007/s00198-006-0094-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00198-006-0094-1

Keywords

Search

Navigation